The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA.
MEDI-565 (also known as MT111) is a bispecific T-cell engager (BiTE®) antibody in development for the treatment of patients with cancers expressing carcinoembryonic antigen (CEA). MEDI-565 binds CEA on cancer cells and CD3 on T cells to induce T-cell mediated killing of cancer cells. To understand t...
Main Authors: | Li Peng, Michael D Oberst, Jiaqi Huang, Philip Brohawn, Chris Morehouse, Kristen Lekstrom, Patrick A Baeuerle, Herren Wu, Yihong Yao, Steven R Coats, William Dall'Acqua, Melissa Damschroder, Scott A Hammond |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3344869?pdf=render |
Similar Items
-
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids
by: Reyes Gonzalez-Exposito, et al.
Published: (2019-04-01) -
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
by: Pan H, et al.
Published: (2018-05-01) -
The prognostic value of the postoperative serum CEA levels/preoperative serum CEA levels ratio in colorectal cancer patients with high preoperative serum CEA levels
by: Xie HL, et al.
Published: (2019-08-01) -
Immunisierung gegen das Tumorantigen CEA: Vergleichende Untersuchung an Wildtyp- und CEA transgenen Mäusen
by: Muders, Michael H.
Published: (2003) -
Bi-epitope SPR surfaces: a solution to develop robust immunoassays.
by: Li Peng, et al.
Published: (2014-01-01)